← Russell 3000 cross-section

EOLS Evolus, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$592m
Revenue TTM
$316m
Net income TTM
$-34m
Free cash flow
$-18m
Composite score
34.4
Sector rank
#2318

Valuation

P / E
EV / EBITDA
EV / sales
2.2
FCF yield
-3.09%
Earnings yield vs 10-yr
-10.52pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-10.8%
EBITDA margin
-3.1%
ROE
111.1%
ROIC
-23.1%
Revenue growth
13.9%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Net revenues increased by $14.7 million, or 21.2%, to $84.1 million in the three months ended June 30, 2026 from $69.4 million in the three months ended June 30, 2025, primarily due to higher Jeuveau ® sales. Cost of goods sold increased by $2.8 million, or 11.8%, to $26.9 million in the three months ended June 30, 2026 from $24.1 million in the three months ended June 30, 2025, primarily attributable to higher volumes of products shipped to customers, partially offset by a reduction in cost of goods sold of $1.1 million resulting from the recognition of IEEPA tariff refunds. …Evolus, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →